Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | recruiting | Phase 1 / Phase 2 | 66 | Anbogen Therapeutics, Inc.INDUSTRY | 2 | Nov 24, 2025 | clinicaltrials |
| NCT03926338 | Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer(PICC) | recruiting | Phase 2 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05748145 | Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 | recruiting | Phase 2 | 40 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07106892 | Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07130903 | Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer | recruiting | Phase 2 | 102 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05040815 | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer(INSPIRE) | recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204574 | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06008054 | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors | recruiting | Phase 2 | 376 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07140679 | Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | recruiting | Phase 2 | 40 | Emory UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06368141 | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer(NeoCHIC) | recruiting | Phase 2 | 56 | Ruijin HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154316 | Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05706779 | Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer(NEORAF) | recruiting | Phase 2 | 30 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06887218 | 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06856187 | Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL) | recruiting | Phase 2 | 119 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07095439 | Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients | recruiting | Phase 2 | 38 | Ain Shams UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT05571644 | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer(OPTICAL-2) | recruiting | Phase 2 | 143 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06873763 | Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 52 | STCube, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06630624 | Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM(INJECTABL-II) | recruiting | Phase 1 / Phase 2 | 120 | M.R. MeijerinkOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07047560 | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05310643 | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC(NIPIRESCUE) | recruiting | Phase 2 | 30 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05775146 | SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases | recruiting | Phase 2 | 24 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06885385 | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | recruiting | Phase 2 | 60 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05771181 | Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05908643 | A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 16 | Neogap Therapeutics ABINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06991465 | Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)(Hypo-OPRA) | recruiting | Phase 2 | 35 | Neil KopekOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05870800 | Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER(NICER) | recruiting | Phase 2 | 28 | Baylor College of MedicineOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06979908 | A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 46 | The First Hospital of Jilin UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06980532 | Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 42 | Liu HuangOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03401294 | Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.(CONVERSION) | recruiting | Phase 2 | 32 | University of SaskatchewanOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06949982 | Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes(x-МАР) | recruiting | Phase 2 | 60 | Sergey Orlov, MDOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05965531 | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy(TASLARC) | recruiting | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2025source: clinicaltrials